Early GLP-1 aging-clock findings are interesting but preliminary. We explain what was measured, the limits of the evidence, and practical ways to protect strength after 50.
In October 2026, a chart went viral on X: in a small group of people taking tirzepatide (sold as Mounjaro and Zepbound), every one of 15 "epigenetic aging clocks" ticked more slowly than the calendar. Within days, headlines asked whether weight-loss drugs had become the first real anti-aging pills. The honest answer is that the data are interesting, early and heavily caveated. Here is what was actually measured, how much weight it can bear, and what you can do after 50 without a prescription.
Both big GLP-1 makers presented aging-clock data at the Aging Research and Drug Discovery (ARDD) meeting in 2026, as reported by MIT Technology Review (6 October 2026) and MedPath.
Eli Lilly (tirzepatide). The data came from an epigenetic sub-study inside SURMOUNT-5, Lilly's head-to-head trial comparing tirzepatide with semaglutide in adults with obesity but without diabetes. Researchers took whole-blood samples from tirzepatide-treated participants at baseline and at week 72, which is 1.38 years of elapsed time. After quality control the analysis covered 82 people, 71 of whom had both samples; Scripps News reports the group was over 50. Two labs, Zymo Research and TruDiagnostic, generated the DNA-methylation data independently so the results could be cross-checked.
Novo Nordisk (semaglutide). Novo analysed blood from 10,052 people across five semaglutide trials, half on the drug and half on placebo, using "proteomic clocks" built from protein levels. It reported predicted biological ages roughly two to three years lower than placebo, and up to about four years on a clock tracking heart-related proteins. This work was released as a preprint.
Lilly's Kevin Duffin summed it up: "All the clocks are telling a consistent story that we're seeing a reduction in age. It's not like we're going to reverse age by 30 years or something."
Lilly itself called the findings preliminary and "hypothesis-generating", and the caveats are substantial.
1. No placebo or control group. SURMOUNT-5 compared two active drugs; it had no placebo arm. The sub-study only sampled the tirzepatide group and compared clock readings with elapsed calendar time, not with untreated people. Some coverage described a comparison "with placebo"; for Lilly's data that is not accurate.
2. Small and short. 71 paired samples over 72 weeks is a pilot. Lilly noted that the follow-up was short relative to the measurement error of the clocks.
3. Mixed signals. Only 2 of 15 clocks were statistically significant. Some signals were discordant, and several predicted protein changes did not match the measured proteins.
4. Conference data, not peer reviewed. The Lilly results were presented at a meeting, and Novo's work is a preprint. Neither has passed full peer review.
5. Clocks are surrogates, not outcomes. Novo's own preprint says proteomic age models "are predictive biomarkers rather than established mechanistic measures of biological aging", and that a lower reading should not be read "as proof of biological rejuvenation." Nobody measured lifespan, frailty or disease-free years.
6. Commercial context. Both studies were run by the companies that sell the drugs. Neither Zepbound's nor Wegovy's label lists aging as an indication.
Tirzepatide produces large weight loss; in SURMOUNT-5 it outperformed semaglutide. Many aging clocks are trained partly on signals of metabolic health, inflammation and mortality risk. Those signals improve whenever a person with obesity loses a lot of weight, whatever the method.
Lilly itself drew parallels with calorie-restriction and bariatric-surgery studies, where clocks also tend to move favourably. So the most cautious reading is: substantial weight loss in people with obesity improves molecular risk markers, and tirzepatide is a very effective way to produce that weight loss. Whether the drug does anything to aging beyond the weight loss is the open question, and this design cannot answer it.
That doesn't make the result worthless. Lower inflammation and better metabolic health are good things in themselves. But "slows aging" is a much bigger claim than the data support.
One caveat matters especially for older readers: rapid weight loss, from drugs or diet, includes some loss of lean mass. After 50, muscle and bone are already declining, and holding on to strength is one of the best-established predictors of independence and survival. If you are on a GLP-1 drug, protein intake and resistance training are worth discussing with your doctor. If you are not, the same habits are your best lever anyway.
None of these are shortcuts, but each has far more evidence behind it than any aging clock.
Resistance training is the most reliable way to build and keep muscle and bone at any age. Public-health guidelines (WHO, CDC) recommend muscle-strengthening activity on two or more days a week. Progressive loading of the hips and spine also supports bone density; see our coverage of bone-loading training.
The PROT-AGE expert group (Bauer et al., *JAMDA*, 2013) recommends that older adults aim for about 1.0–1.2 g of protein per kg of body weight per day, more during illness or for active people, rather than the older 0.8 g/kg minimum. A meta-analysis by Cermak et al. (*Am J Clin Nutr*, 2012) found that protein supplementation increases gains in lean mass and strength from resistance training, including in older adults. Food comes first. If you struggle to reach your target, a plain whey or plant protein powder is a convenient top-up:
Creatine monohydrate is one of the most studied supplements. Meta-analyses in older adults (for example Chilibeck et al., *Open Access J Sports Med*, 2017) find that creatine combined with resistance training gives modestly larger gains in lean mass and strength than training alone. It does little without the training. People with kidney disease should talk to their doctor first.
Walking and aerobic activity (about 150 minutes a week of moderate activity, per WHO) are among the strongest predictors of lower mortality. Regular sleep and limiting alcohol also support the metabolic markers that aging clocks track.
Instead of chasing a clock score, track things that matter: grip strength, how many chair stands you can do in 30 seconds, walking speed, waist size, blood pressure, and blood glucose and lipids from your doctor.
That is a decision for you and your doctor, based on approved uses such as obesity, type 2 diabetes or cardiovascular risk, not on aging-clock readings. Stacking Years does not give drug dosing advice. For people who already qualify, the aging-clock data are a possible extra benefit to watch. For everyone else, they are not a reason to start.
*This article is for information only and is not medical advice. Talk to your doctor before starting or changing any medication or supplement.*